Kyle Gano

Chief Executive Officer & Director, NEUROCRINE BIOSCIENCES INC

Search every verified Kyle Gano interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Kyle Gano, Chief Executive Officer of Neurocrine Biosciences, spoke on the company’s first-quarter 2026 earnings call, reporting that quarterly net product sales exceeded $800 million for the first time in company history, a 44% year-over-year increase. He attributed this growth primarily to Ingrezza, now in its ninth year on the market, and noted continued momentum across the commercial portfolio and clinical pipeline. Gano also addressed the pending acquisition of Seno Therapeutics, stating that the deal remained on track to close in the second quarter, though he said the company would be limited in discussing it during the call due to the ongoing tender offer. He praised Seno’s team for its clinical results and the launch of Vihaan XR. . . Gano additionally described recent engagement with the endocrinology community, including attendance at the Pediatric Endocrine Society meeting, where he said sessions on CRENESSITY were well attended and that physician enthusiasm for the treatment was evident. He noted that patient out-of-pocket costs for CRENESSITY were low, typically under $10 per month, and that affordability had not been a significant reason for discontinuation, with persistency remaining strong about five quarters into the launch.